nach oben

International Urogynecology Journal

Erschienen in:

01.12.2012 | Original Article

Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study

verfasst von: Davide De Vita, Salvatore Giordano

Erschienen in: International Urogynecology Journal | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

The glycosaminoglycan hyaluronic acid (HA) protects the urothelium; damage may increase bacterial adherence and infection risk. This study evaluated the effect of intravesical HA in recurrent bacterial cystitis (RBC).

Methods

Women with RBC were randomized to intravesical HA 800 mg and chondroitin sulfate (CS) 1 g (IALURIL^®, IBSA) in 50 mL of saline solution once weekly for 4 weeks then once every 2 weeks twice more (group 1) or long term antibiotic prophylaxis using sulfamethoxazole 200 mg and trimethoprim 40 mg once weekly for 6 weeks (group 2; control). Evaluations included: cystitis recurrence at 2 and 12 months; subjective pain symptoms (visual analog scale [VAS]); 3 day voiding; sexual function; quality of life (King's Health Questionnaire [KHQ]); frequency symptoms/frequency symptoms (PUF symptom scale); and maximum cystometric capacity (MCC). Means ± standard deviations were reported, with Mann-Whitney test for between-group comparison (significance P < .05).

Results

Of 28 women (mean age 60 ± 13 y) randomized, 26 completed follow-up (mean follow-up 11.5 mo). Group 1 showed a significant improvement in all evaluations; cystitis recurrence (1 ± 1.2 versus 2.3 ± 1.4, P = .02); 3-day voiding (mean 17.8 ± 3.5 vs 24.2 ± 8.3, P = .04); symptom VAS (1.6 ± 0.8 vs 7.8 ± 1.6, P < .001); PUF score (11.2 ± 2.7 vs 19.6 ± 2.2, P < .001), KHQ score (18.4 ± 7.2 vs 47.3 ± 13.6, P < .001), and MCC (380 ± 78 vs 229 ± 51 mL, P < .001) vs group 2 at 12 mo. No adverse effects were recorded.

Conclusions

Intravesical HA and CS in combination significantly reduced cystitis recurrence and improved urinary symptoms, quality of life, and cystometric capacity in RBC patients at 12 mo follow-up versus antibiotic prophylaxis. Study limitations include a small sample and relatively short follow-up.

Foxman B (2002) Epidemiology of urinary tract infections: incidence, morbidity and economic costs. Am J Med 113:5S–13SPubMedCrossRef

Ronald A (2002) The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 113:14S–19SPubMedCrossRef

Chung A, Arianayagam M, Rashid P (2010) Bacterial cystitis in women. Aust Fam Physician 39(5):295–298PubMed

Foxman B, Gillespie B, Koopman J, Zhang L, Palin K, Tallman P et al (2000) Risk factors for second urinary tract infection among college women. Am J Epidemiol 151:1194–1205PubMedCrossRef

Avorn J, Monane M, Gurwitz JH, Glynn RJ, Choodnovskiy I, Lipsitz LA (1992) Reduction of bacteriuria and pyuria after ingestion of cranberry juice. J Am Med Assoc 271:751–754CrossRef

Raz R, Stamm WE (1993) A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329:753–756PubMedCrossRef

Reid G (1999) The scientific basis for probiotic strains of Lactobacillus. Appl Environ Microbiol 65:3763–3766PubMed

Schulman CC, Corbusier A, Michiels H, Taenzer HJ (1993) Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study. J Urol 150:917–921PubMed

Kruze D, Holzbecher K, Andrial M, Bossart W (1989) Urinary antibody response after immunisation with a vaccine against urinary tract infection. Urol Res 17:361–366PubMedCrossRef

10.

Schilling JD, Mulvey MA, Hultgren SJ (2001) Dynamic interactions between host and pathogen during acute urinary tract infections. Urology 57:56–61PubMedCrossRef

11.

Reid G (1999) Current scientific understanding of urinary tract infections in women: an overview. World J Urol 17:336–338PubMedCrossRef

12.

Gupta K, Stamm WE (1999) Pathogenesis and management of recurrent urinary tract infections in women. World J Urol 17:415–420PubMedCrossRef

13.

Poggi MM, Johnstone PAS, Conner RJ (2000) Glycosaminoglycan content of human bladders: a method of analysis using coldcup biopsies. Urol Oncol 5:234–237PubMedCrossRef

14.

Morales A, Emerson L, Nickel JC (1997) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology 49:111–113PubMedCrossRef

15.

Parsons CL (1997) Epithelial coating techniques in the treatment of interstitial cystitis. Urology 49:100–104PubMedCrossRef

16.

Daha LK, Riedl CR, Hohlbrugger G, Knoll M, Engelhardt PF, Pflüger H (2003) Comparative assessment of maximal bladder capacity, 0.9% NaCl versus 0.2 M KCl, for diagnosis of interstitial cystitis: prospective controlled study. J Urol 170:807–809PubMedCrossRef

17.

Shao Y, Shen ZJ, Rui WB, Zhou WL (2010) Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis. Urology 75(3):547–550PubMedCrossRef

18.

Porru D, Leva F, Parmigiani A, et al (2011) Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol. doi:10.1007/s00192-011-1546-5

19.

Constantinides C, Manousakas T, Nikolopoulos P, Stanitsas A, Haritopoulos K, Giannopoulos A (2004) Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int 93(9):1262–1266PubMedCrossRef

20.

Lipovac M, Kurz C, Reithmayr F, Verhoeven HC, Huber JC, Imhof M (2007) Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet 96(3):192–195PubMedCrossRef

21.

Damiano R, Quarto G, Bava I et al (2011) Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol 59(4):645–651PubMedCrossRef

22.

Gillenwater JY, Wein AJ (1987) Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987. J Urol 140(1):203–206

23.

Ronald AR, Harding CK, Mathias R, Wong CK, Muir P (1975) Prophylaxis of recurring urinary tract infection in females: a comparison of nitrofurantoin with trimethoprim-sulfamethoxazole. Can Med Assoc J 112(13 Spec No):13–16PubMed

24.

Salomon J, Denys P, Merle C, Chartier-Kastler E, Perronne C, Gaillard JL, Bernard L (2006) Prevention of urinary tract infection in spinal cord-injured patients: safety and efficacy of a weekly oral cyclic antibiotic (WOCA) programme with a 2 year follow-up–an observational prospective study. J Antimicrob Chemother 57(4):784–788PubMedCrossRef

25.

Ito T, Tomoe H, Ueda T, Yoshimura N, Sant G, Hanno P (2003) Clinical symptoms scale for interstitial cystitis for diagnosis and for following the course of the disease. Int J Urol 10:S24–26PubMedCrossRef

26.

Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104(12):1374–1379PubMedCrossRef

27.

Figueiredo AB, Palma P, Riccetto C, Herrmann V, Dambros M, Capmartin R (2011) Clinical and urodynamic experience with intravesical hyaluronic acid in painful bladder syndrome associated with interstitial cystitis. Actas Urol Esp 35(3):184–7PubMedCrossRef

28.

Leppilahti M, Hellström P, Tammela TL (2002) Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology 60(1):46–51PubMedCrossRef

29.

Lee DG, Cho JJ, Park HK et al (2010) Preventive effects of hyaluronic acid on Escherichia coli-induced urinary tract infection in rat. Urology 75(4):949–954PubMedCrossRef

30.

Fraser MO, Lavelle JP, Sacks MS, Chancellor MB (2002) The future of bladder control-intravesical drug delivery, a pinch of pepper, and gene therapy. Rev Urol 4(1):1–11PubMed

31.

Schulz A, Vestweber AM, Dressler D (2009) Anti-inflammatory action of a hyaluronic acid-chondroitin sulfate preparation in an in vitro bladder model. Aktuelle Urol 40(2):109–12PubMedCrossRef

32.

Southgate J, Varley CL, Garthwaite MA, Hinley J, Marsh F, Stahlschmidt J et al (2007) Differentiation potential of urothelium from patients with benign bladder dysfunction. BJU Int 99(6):1506–1516PubMedCrossRef

33.

Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR (2010) Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 22(4):401–405

34.

Burkhard FC, Blick N, Hochreiter WW, Studer UE (2004) Urinary urgency and frequency, and chronic urethral and/or pelvic pain in females. Can doxycycline help? J Urol 172(1):232–235PubMedCrossRef

35.

Hooton TM (2001) Recurrent urinary tract infection in women. Int J Antimicrob Agents 17:259–268PubMedCrossRef

Titel: Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study
verfasst von: Davide De Vita
Salvatore Giordano
Publikationsdatum: 01.12.2012
Verlag: Springer-Verlag
Erschienen in: International Urogynecology Journal / Ausgabe 12/2012
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-012-1794-z

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2012

Vaginal incisional wound healing in a rabbit menopause model: A histologic analysis

Vaginal repair of supratrigonal vesicovaginal fistulae—a 10-year review

Clinical evaluation of a wireless intra-vaginal pressure transducer

Does the G-spot exist? A review of the current literature

My journey as urogynaecologist

The urethra is a reliable witness: simplifying the diagnosis of stress urinary incontinence

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie